This Vaccination Strategy Can Prevent Coronavirus, According to a New Research
Researchers in Japan have developed a vaccination strategy in mice that promotes the production of antibodies that can neutralize now not only SARS-CoV-2 but a extensive range of other coronaviruses as well. If successfully translated to humans, the approach, to be posted today (October 8, 2021), in the Journal of Experimental Medicine, should lead to the development of a next-generation vaccine capable of preventing future coronavirus pandemics.
The SARS-CoV-2 virus responsible for COVID-19 enters human cells by using its spike protein to bind to a mobile surface receptor called ACE2. The receptor-binding domain of the spike protein consists of two parts: a “core” region that is very similar in all coronaviruses, and a more specialized “head” region that mediates binding to ACE2.
Antibodies that recognize the head region of the spike receptor-binding area can block the entry of SARS-CoV-2 into cells but offer little protection against different coronaviruses, such as the SARS-CoV-1 virus accountable for the severe acute respiratory syndrome outbreak of 2002. Antibodies that recognize the core region of the spike receptor-binding domain, in contrast, can prevent the entry of various coronaviruses into human cells. Unfortunately, however, individuals exposed to the viral spike protein tend to produce lots of antibodies in opposition to the head region but few, if any, antibodies that recognize the core region.
“This suggests that, although the generation of broadly neutralizing antibodies is possible, SARS-CoV-2 contamination and current vaccines are unlikely to provide protection against the emergence of novel SARS-related viruses,” explains Professor Tomohiro Kurosaki from the WPI Immunology Frontier Research Center at Osaka University in Japan. “Given that prior coronavirus epidemics such as SARS-CoV-1 and MERS-CoV have occurred due to zoonotic coronaviruses crossing the species barrier, the potential for the emergence of comparable viruses in the future poses a significant threat to global public health, even in the face of effective vaccines for current viruses.”
Kurosaki and colleagues decided to test a new vaccination strategy that might enable the immune system to produce more broadly neutralizing antibodies. The researchers genetically engineered the receptor-binding domain of the SARS-CoV-2 spike protein, covering its head region in extra sugar molecules. These sugar molecules could shield the head region from the immune system and increase the production of antibodies against the unshielded core region of the receptor-binding domain.
Indeed, mice immunized with these engineered proteins produced a much greater proportion of antibodies recognizing the core region of the spike protein receptor-binding domain. These antibodies have been able to neutralize the cellular entry of not only SARS-CoV-2 however also SARS-CoV-1 and three SARS-like coronaviruses from bats and pangolins.
Much work will need to be done to translate this strategy to humans, but, says Kurosaki, “our data suggest that engineered versions of the spike receptor-binding domain could be a useful component for the development of broadly protective, next-generation vaccines to prevent future coronavirus pandemics.”
Originally published: Sci Tech Daily
Reference: “Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses” 8 October 2021, Journal of Experimental Medicine.